The epidemiology of dry eye disease

Article

It is clear that the previously underappreciated condition of dry eye disease should now be regarded as a serious public health problem that is worthy of diagnosis and effective treatment.

Key Points

Considerable progress has been made in the last 15 years regarding our knowledge on the epidemiology of dry eye disease. As we describe in this article, dry eye disease is a major and increasing healthcare problem due to its prevalence, and impact on patients' quality of life, healthcare resources and the economy. It is clear that this previously underappreciated condition should now be regarded as a serious public health problem that is worthy of diagnosis and effective treatment.

Definition of dry eye disease

It has been discovered that dry eye disease is caused by conditions that increase evaporation of the tear film or decrease tear production. The resulting increase in tear film osmolarity (hyperosmolarity) leads to ocular surface inflammation, damage, and symptoms such as dryness, burning or stinging, ocular grittiness, foreign body sensation, blurred or fluctuating vision, watery eyes, and photophobia.

"... a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface."

Problems with establishing prevalence

Epidemiological studies show wide differences in prevalence. Estimating the prevalence of dry eye disease is problematic because there is no consensus on diagnostic criteria. Another reason for the variation in prevalence estimates may be a true heterogeneity in dry eye prevalence in different populations.

A review of several large studies, conducted by the Epidemiology Subcommittee of the 2007 DEWS, showed that the prevalence of dry eye ranges between 5% and 30% in people aged >50 years.1 Considering the different definitions used in these studies, the DEWS group concluded that the true prevalence of moderate-to-severe dry eye lies somewhere close to the lower end of the range, whereas inclusion of mild or episodic cases would bring the estimate closer to the higher estimates reported.

A further difficulty in establishing the extent of dry eye disease is the fact that it is an underdiagnosed condition. Many patients mistakenly attribute dry eye symptoms to other causes, such as "getting older", and assume the symptoms are simply "something they have to live with." As a result, many patients tend to endure the condition or to self-treat with over-the-counter products, without consulting a physician or obtaining a definitive diagnosis. Indeed, the results of the 2005 Gallup Survey of Dry Eye Sufferers suggests that one in four people with dry eye do not consult a health care professional about their condition.2

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.